ERIN VINCENT: Open Payments
NPI 1487985065 · BLOOMFIELD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,483 in 56 payments from 16 companies in 2025. Trend: 2023 $687 · 2024 $1,572 · 2025 $1,483
Food & beverage: $1,483
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $248 |
| Abbott Laboratories | 2 | $170 |
| Edwards Lifesciences Corporation | 1 | $159 |
| E.R. Squibb & Sons, L.L.C. | 11 | $143 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $107 |
| AstraZeneca Pharmaceuticals LP | 5 | $99 |
| Amgen Inc. | 4 | $90 |
| SCPHARMACEUTICALS INC. | 5 | $80 |
| ABIOMED | 2 | $67 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $59 |
Products named: LEQVIO, CARDIOMEMS, JARDIANCE, CAMZYOS, REPATHA, FUROSCIX, FARXIGA, Kerendia.
Industry payments across CT — which companies pay providers there.
